BioSpace News Archive

bioLytical Laboratories Inc. announced that it is launching a second test on its new platform, iStatis, after receiving Health Canada authorization for the iStatis COVID-19 Antigen Home Test for its immediate market entry into Canada.

Sanofi announced that the French Autorité des marchés financiers has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.

RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., and Quantum Leap Healthcare Collaborative, have announced that the nebulized form of aviptadil being used in the I-SPY COVID Trial of critical COVID-19 patients has been stopped.

Akeso, Inc., a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, reported 2021 annual results.

RELIEF THERAPEUTICS Holding SA reported that the Swiss Patent Office IPI has issued a patent WO2020/225246 entitled, “Vasoactive Intestinal Peptide for the Use in the Treatment of Drug-induced Pneumonitis,” to Relief’s subsidiary, AdVita Lifescience GmbH.

Royal Philips, a global leader in health technology, is showcasing its integrated portfolio of diagnosis, guidance, and treatment solutions for atrial fibrillation at the 2022 European Heart Rhythm Association Annual Meeting.

Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced the successful completion of the first-in-human dose escalating study of ZZ6398 in healthy volunteers.

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved or mildly reduced ejection fraction.

Sage Therapeutics, Inc. announced the presentation of data from the Phase 2 LUMINARY Study that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease.

Eli Lilly and Company announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® in patients with RET fusion-positive non-small cell lung cancer.